Skip to main content
. 2022 Aug 30;31(8):3079–3090. doi: 10.1007/s00167-022-07101-4

Fig. 2.

Fig. 2

Changes in patients reported outcome measures. Changes at 6 and final follow-up (calculated as value at follow-up – value at baseline) for VAS (A), KOOS-PS (B), KOOS-PS Activity subscale (C), KOOS-PS Function subscale (D), WOMAC (E), SF-12 Physical Component Score (F) and SF-12 Mental Component Score (G). Concerning KSS (H) and its functional subscale (I) values were collected at baseline and 6-month follow-up only. *p < 0.05, **p < 0.01, ***p < 0.001 vs baseline (within-group difference); §p < 0.1 (tendency), #p < 0.05, ##p < 0.01 vs AD group (between-group difference). Clinical improvements are represented as decreases in VAS, KOOS-PS Activity subscale, KOOS-PS Function subscale and WOMAC, and as increases in KOOS-PS, KSS, KSS Function subscale, SF-12 MCS and SF-12 PCS